Breaking News Instant updates and real-time market news.

HALO

Halozyme

$15.55

0.25 (1.63%)

07:05
11/04/19
11/04
07:05
11/04/19
07:05

Halozyme says HALO-301 Phase 3 study fails to meet primary endpoint

Halozyme Therapeutics announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the primary endpoint of overall survival. The treatment arm of PEGPH20 in combination with gemcitabine and nab-paclitaxel failed to demonstrate an improvement in median overall survival compared to gemcitabine and nab-paclitaxel alone. While there was a higher response rate in the PEGPH20 treatment arm, this did not translate into an improvement in duration of response, Progression Free Survival or Overall Survival. "Patients in both treatment arms of the HALO-301 trial surpassed the published median overall survival rates from the pivotal registration study of ABRAXANE plus gemcitabine as first-line therapy for metastatic pancreas cancer, published in 2013. Based on the lack of benefit over standard-of-care in this study, which performed well versus published data, we will be discontinuing PEGPH20 clinical development," said Dr. Helen Torley, president and CEO of Halozyme. "This well-designed and well-executed study did not have the outcome that we or the study participants wanted or expected. I would like to extend a heartfelt thank you to all those who supported and who made this study possible, including the patients who were enrolled, their families, our investigators, their staff, our investors and all of the dedicated Halozyme employees." Halozyme intends to halt development activities for PEGPH20 and implement an organizational restructuring to focus its operations solely on its ENHANZE drug delivery technology.

  • 12

    Nov

HALO Halozyme
$15.55

0.25 (1.63%)

01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.
07/01/19
CANT
07/01/19
NO CHANGE
Target $27
CANT
Overweight
Halozyme price target raised to $27 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $27 from $24 after including potential future royalty revenues from Enhanze-enhanced drugs developed by partner companies. The analyst continues to view the approval and launch of the Enhanze-based products as "fueling sustainable revenue growth" through 2027, with the Darzalex program as the near-term driver. He sees "notable potential" share upside "almost irrespective" of the outcome of the HALO-301 Phase trial in pancreatic cancer later in 2019. Duncan reiterates an Overweight rating on Halozyme.
09/11/19
CANT
09/11/19
NO CHANGE
CANT
Overweight
Halozyme offers 'low-risk/high-reward' event in Q4, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on shares of Halozyme Therapeutics after a meeting with the company's CEO left him believing that a "clear read" will be seen with the HALO-301 trial in pancreatic cancer later in 2019. However, the analyst continues to see Halozyme share upside "almost irrespective" of the outcome of the Phase 3 trial in Q4. Investors appreciate the high risk in pancreatic cancer, says Duncan, who sees low expectations for Phase 3 success being priced into the current share price. The company's "growing" Enhanze franchise is the major driver of share value going forward post the HALO-301 readout, Duncan contends. He likes the design and rationale of the study, and therefore sees it as a "low-risk/high-reward" binary event.

TODAY'S FREE FLY STORIES

EDIT

Editas Medicine

$30.34

-0.6 (-1.94%)

18:02
12/09/19
12/09
18:02
12/09/19
18:02
Hot Stocks
Editas Medicine announces in vivo proof-of-concept data for EDIT-301 »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

, CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

17:56
12/09/19
12/09
17:56
12/09/19
17:56
Hot Stocks
Mesabi Trust initiates arbitration against Northshore Mining, Cleveland-Cliffs »

The Trustees of Mesabi…

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$24.67

0.12 (0.49%)

17:51
12/09/19
12/09
17:51
12/09/19
17:51
Hot Stocks
First Financial Bancorp chairman Davis sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRE

Green Plains

$14.26

-0.49 (-3.32%)

17:47
12/09/19
12/09
17:47
12/09/19
17:47
Hot Stocks
Green Plains CEO Todd Becker sold over 607K in company shares »

Green Plains CEO Todd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$111.12

-2.02 (-1.79%)

17:43
12/09/19
12/09
17:43
12/09/19
17:43
Hot Stocks
Medtronic director buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

VAC

Marriott Vacations

$123.77

-0.1 (-0.08%)

17:41
12/09/19
12/09
17:41
12/09/19
17:41
Hot Stocks
Marriott Vacations raises quarterly dividend to 54c from 45c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLY

Fastly

$20.82

-0.35 (-1.65%)

17:36
12/09/19
12/09
17:36
12/09/19
17:36
Hot Stocks
Fastly director Sunil Dhaliwal sells almost $576K in company shares »

Fastly director Sunil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

17:36
12/09/19
12/09
17:36
12/09/19
17:36
Hot Stocks
Stitch Fix says saw healthy growth in both women's, men's categories »

Says shows online…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

F

Ford

$9.00

-0.015 (-0.17%)

17:32
12/09/19
12/09
17:32
12/09/19
17:32
Hot Stocks
Ford expects to roughly halve 2018 China EBIT loss »

During a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 07

    Jan

  • 04

    Feb

VEEV

Veeva

$143.56

-1.115 (-0.77%)

17:28
12/09/19
12/09
17:28
12/09/19
17:28
Hot Stocks
Veeva CMO sells 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BLDR

Builders FirstSource

$25.71

0.45 (1.78%)

17:25
12/09/19
12/09
17:25
12/09/19
17:25
Hot Stocks
Builders FirstSource acquires assets of Raney Components, Construction »

Builders FirstSource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

S

Sprint

$5.40

-0.145 (-2.62%)

, TMUS

T-Mobile

$75.90

-1.87 (-2.40%)

17:16
12/09/19
12/09
17:16
12/09/19
17:16
Periodicals
Judge seeks speedy trial over T-Mobile, Sprint deal, WSJ reports »

U.S. District Judge…

S

Sprint

$5.40

-0.145 (-2.62%)

TMUS

T-Mobile

$75.90

-1.87 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 16

    Dec

WEN

Wendy's

$21.72

0.15 (0.70%)

17:15
12/09/19
12/09
17:15
12/09/19
17:15
Hot Stocks
Wendy's sees FY20 FCF of $210M-$220M including impact of settlement »

As a result of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BANX

StoneCastle

$22.99

0.25 (1.10%)

17:15
12/09/19
12/09
17:15
12/09/19
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneCastle »

StoneCastle trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIZ

Assurant

$130.91

-0.66 (-0.50%)

17:14
12/09/19
12/09
17:14
12/09/19
17:14
Hot Stocks
Assurant director sells 21.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XAIR

Beyond Air

$4.13

0.005 (0.12%)

17:14
12/09/19
12/09
17:14
12/09/19
17:14
Syndicate
Beyond Air announces offering of common stock, concurrent private placement »

Beyond Air announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$151.35

-0.42 (-0.28%)

, UPWK

Upwork

$11.15

-0.16 (-1.41%)

17:10
12/09/19
12/09
17:10
12/09/19
17:10
Hot Stocks
Upwork CEO Stephane Kasriel to step down, Hayden Brown to succeed »

Upwork (UPWK) announced…

MSFT

Microsoft

$151.35

-0.42 (-0.28%)

UPWK

Upwork

$11.15

-0.16 (-1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AMZN

Amazon.com

$1,749.61

-1.18 (-0.07%)

, MSFT

Microsoft

$151.35

-0.42 (-0.28%)

17:10
12/09/19
12/09
17:10
12/09/19
17:10
On The Fly
Fly Intel: Wall Street's top stories for Monday »

Stocks slid to kick off…

AMZN

Amazon.com

$1,749.61

-1.18 (-0.07%)

MSFT

Microsoft

$151.35

-0.42 (-0.28%)

ARQL

ArQule

$19.71

10.035 (103.77%)

THOR

Synthorx

$67.72

42.74 (171.10%)

SNY

Sanofi

$45.30

-0.755 (-1.64%)

DPLO

Diplomat Pharmacy

$3.91

-1.91 (-32.82%)

UNH

UnitedHealth

$277.56

-2.62 (-0.94%)

MS

Morgan Stanley

$49.60

-0.2 (-0.40%)

VIAC

ViacomCBS

$38.65

-1.05 (-2.64%)

VIACA

ViacomCBS

$41.78

-1.64 (-3.78%)

FTSV

Forty Seven

$30.44

16.04 (111.39%)

FATE

Fate Therapeutics

$19.32

5.68 (41.64%)

TTWO

Take-Two

$120.07

-3.69 (-2.98%)

THO

Thor Industries

$64.28

-3.485 (-5.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

BANX

StoneCastle

$22.99

0.25 (1.10%)

17:09
12/09/19
12/09
17:09
12/09/19
17:09
Hot Stocks
ArrowMark Partners to acquire StoneCastle Asset Management »

StoneCastle Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$21.72

0.15 (0.70%)

17:08
12/09/19
12/09
17:08
12/09/19
17:08
Hot Stocks
Wendy's to realign resources in its information technology organization »

On December 5, the Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

INVH

Invitation Homes

$30.14

0.12 (0.40%)

17:05
12/09/19
12/09
17:05
12/09/19
17:05
Hot Stocks
Invitation Homes sells 708 Nashville homes to Tricon for $210M »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRO

Brown & Brown

$38.22

-0.14 (-0.36%)

17:04
12/09/19
12/09
17:04
12/09/19
17:04
Hot Stocks
Brown & Brown enters agreement to acquire Special Risk Insurance Managers »

J. Scott Penny, Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PYX

Pyxus

$7.40

-0.345 (-4.45%)

, PM

Philip Morris

$83.60

0.34 (0.41%)

17:02
12/09/19
12/09
17:02
12/09/19
17:02
Hot Stocks
Alliance One expands relationship with Philip Morris' Argentine affiliate »

Alliance One…

PYX

Pyxus

$7.40

-0.345 (-4.45%)

PM

Philip Morris

$83.60

0.34 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$89.69

0.2 (0.22%)

17:01
12/09/19
12/09
17:01
12/09/19
17:01
Hot Stocks
Tyson Fresh Meats signs agreement with Republic of Kazakhstan »

Tyson Fresh Meats, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AES

AES Corp.

$18.79

0.07 (0.37%)

17:01
12/09/19
12/09
17:01
12/09/19
17:01
Hot Stocks
AES Corp. raises quarterly dividend 5% to 14.33 per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.